Endocrine therapies, such as tamoxifen and aromatase inhibitors for ER+ disease or herceptin, have proven efficacious [167], but may only target the ER+ and HER2-overexpressing mature tumor cell types and not multipotent undifferentiated cancer stem cells [128]. This evidence concerns the gene ERBB2 and cancer.